SCHEMBL6493683

SCHEMBL6493683

Cc1ccc(S(=O)(=O)NC(=O)c2ccc3nc(C)n(Cc4ccc(-c5ccccc5)nc4Cl)c3n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.44
PTGS1 P23219 4/20 0.44
EGFR P00533 3/20 0.39
GFER P55789 1/20 0.38
AGTR2 P50052 1/20 0.37
KAT6A Q92794 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PTGES O14684 2/20 0.37
ALOX5 P09917 2/20 0.37
MAPT P10636 2/20 0.36
GAA P10253 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALKBH2 Q6NS38 1/20 0.36
ALKBH5 Q6P6C2 1/20 0.36
ALKBH3 Q96Q83 1/20 0.36
FTO Q9C0B1 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492855 0.88 PTGS2 (0.47) PTGS2PTGS1EGFRGFERCYP2C9
SCHEMBL6300326 0.87 PTGS2 (0.44) PTGS2PTGS1GFERALDH1A1MEN1
SCHEMBL6135663 0.84 PPARG (0.51) AGTR2ALDH1A1KMT2AMAPTSMN1; SMN2
SCHEMBL6299245 0.84 ALDH1A1 (0.44) PTGS2PTGS1EGFRGFERALDH1A1
SCHEMBL6498182 0.83 DYRK1A (0.39) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL6299877 0.83 PTGS2 (0.44) PTGS2PTGS1GFERALDH1A1KMT2A
SCHEMBL6301176 0.82 KMO (0.43) PTGS2PTGS1EGFRAGTR2ALDH1A1
SCHEMBL6298976 0.82 KMO (0.43) PTGS2PTGS1EGFRAGTR2ALDH1A1
SCHEMBL6301334 0.82 ALDH1A1 (0.44) PTGS2PTGS1GFERALDH1A1MAPT
SCHEMBL6299390 0.82 FLT1 (0.50) PTGS2PTGS1EGFRALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US claimed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US claimed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP claimed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A PTGS2 140/4885PTGS1 86/4885EGFR 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.